3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Breast Neoplasms
7
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma
4
Carcinoma, Non-Small-Cell Lung
4
Burkitt Lymphoma
4
Ovarian Neoplasms
3
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Xerostomia
1
Thyroid Carcinoma, Anaplastic
1
Thrombocytopenia
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Recurrence
1
Prostatic Neoplasms
1
Previously Treated Non Small Cell Lung Cancer
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Pain
1
Osteosarcoma
1
Neutropenia
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Multiple Myeloma
1
Interventions
Filgrastim
8
Cyclophosphamide
8
Cyclosporine
7
fludarabine phosphate
6
Antilymphocyte Serum
6
Rituximab
5
Radiotherapy
5
Peripheral Blood Stem Cell Transplantation
5
Mycophenolic Acid
5
Methotrexate
5
Cord Blood Stem Cell Transplantation
5
Etoposide
4
Busulfan
4
Whole-Body Irradiation
3
Methylprednisolone
3
Melphalan
3
Vincristine
2
Tacrolimus
2
Ifosfamide
2
Granulocyte Colony-Stimulating Factor
2
Doxorubicin
2
Cytarabine
2
Carboplatin
2
Amplified Fragment Length Polymorphism Analysis
2
venetoclax
1
pegfilgrastim
1
obatoclax
1
ibritumomab tiuxetan
1
fludarabine
1
etoposide phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Dendritic Cell Sarcoma, Interdigitating
×
pegfilgrastim
×
Clear all
NCT02531308
2022-09-28
DLBCL
Rush University Medical Center
Phase 2
Terminated
5 enrolled
5 charts